Processa Pharmaceuticals Inc PCSA shares are trading lower by 21.7% to $0.64 Wednesday morning after the company said it recently had a meeting with the FDA about their Next Generation Capecitabine (NGC-Cap) for cancer patients.
The FDA provided guidance on designing the Phase 2 study, protocol and dosage regimen. They anticipate starting enrollment for the Phase 2 study in mid-2024 and believe NGC-Cap might offer a safer and more effective alternative to the existing drug Capecitabine.
The ongoing Phase 1b study's interim results, expected by the end of the year, indicate improved metabolism and distribution of NGC-Cap compared to Capecitabine.
See Also: Fed's 2023 Policy Twists: The Turning Points And Markets Reactions
According to data from Benzinga Pro, PCSA has a 52-week high of $2.24 and a 52-week low of $0.18.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
